Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Frontage Holdings Buys BRI Biopharma, a Canada/US CRO

publication date: Dec 18, 2019

Frontage Holdings (HK: 1521), a US-China CRO, acquired a Vancouver, Canada CRO, BRI Biopharma, which provides pre-clinical and clinical services. Twenty years ago, BRI was founded by Dr. David Kwok, who remains president. Frontage said the acquisition would expand its services to Canada and the west coast of the US. Earlier this year, Frontage completed a $205 million IPO on the Hong Kong exchange, including shares sold by China CRO Tigermed, which continues to own a 51% stake in Frontage after the transaction. Financial terms of the BRI acquisition were not disclosed. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here